Adalimumab in the treatment of psoriasis

( views:212, downloads:0 )
DAI Ting(Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China)
WANG Qian-qiu(Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China)
Journal Title:
International Journal of Dermatology and Venereology
Volume 37, Issue 05, 2011
Key Word:
Psoriasis;Antibodies, monoclonal;Tumor necrosis factor-α

Abstract: Psoriasis is an immune-mediated and chronic inflammatory disease with a great impact on the quality of life. Adalimumab is the first fully human IgGl monoclonal antibody against tumor necrosis factor (TNF) alpha that has been approved abroad for the treatment of moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA). Adalimumab functions by antagonizing the TNF alpha signaling pathway, and has a rapid onset of action, sustained high efficacy and favorable tolerance with no specific organ toxicity. Hence,adalimumab is a prospective drug. Nevertheless, additional studies are warranted to confirm the long-term safety of adalimumab.

  • [1]Weinblatt ME,Keystone EC,Furst DE,et at.Adalimumab,a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial.Arthritis Rheum,2003,48(1):35-45.
  • [2]Victor FC,Gottlieb AB,Menter A.Changing paradigms in dermatology:tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.Clin Dermatol,2003,21 (5):392-397.
  • [3]Schottelius AJ,Moldawer LL,Dinarello CA,et al.Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol,2004,13(4):193-222.
  • [4]Gisondi P,Girolomoni G.Biologic therapies in psoriasis:a new therapeutic approach.Autoimmun Rev,2007,6 (8):515-519.
  • [5]Weisman MH,Moreland LW,Furst DE,et al. Efficacy,pharmacokinetic,and safety assessment of adalimumab,a fully human anti-tumor necrosis factor-alpha monoclonal antibody,in adults with rheumatoid arthritis receiving concomitant methotrexate:a pilot study.Clin Ther,2003,25(6):1700-1721.
  • [6]Santora LC,Kaymakcalan Z,Sakorafas P,et al.Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange,size exclusion chromatography,and BIAcore.Anal Biochem,2001,299 (2):119-129.
  • [7]Gordon KB,Langley RG,Leonardi C,et al.Clinical response to adalimumab treatment in patients with moderate to severe psoriasis:double-blind,randomized controlled trial and openlabel extension study.J Am Acad Dermatol,2006,55 (4):598-606.
  • [8]Saurat JH,Stingl G,Dubertret L,et al.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).Br J Dermatol,2008,158(3):558-566.
  • [9]Menter A,Tyring SK,Gordon K,et al.Adalimumab therapy for moderate to severe psoriasis:A randomized,controlled phase Ⅲ trial.J Am Acad Dermatol,2008,58(1):106-115.
  • [10]Papoutsaki M,Chimenti MS,Costanzo A,et al.Adalimumab for severe psoriasis and psoriatic arthritis:an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol,2007,57(2):269-275.
  • [11]Pitarch G,Sanchez-Carazo JL,Mahiques L,et al.Treatment of psoriasis with adalimumab.Clin Exp Dermatol,2007,32(1):18-22.
  • [12]Jones G,Crotty M,Brooks P.Interventions for psoriatic arthritis.Cochrane Database Syst Rev,2000,(2):CD000212.
  • [13]Kaltwasser JP,Nash P,Gladman D,et al.Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis:a multinational, double-blind, randomized, placebo-controlled clinical trial.Arthritis Rheum,2004,50(6):1939-1950.
  • [14]Mease PJ,Gladman DD,Ritchlin CT,et al.Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial.Arthritis Rheum,2005,52(10):3279-3289.
  • [15]Gladman DD,Mease PJ,Ritchlin CT,et al.Adalimumab for long-term treatment of psoriatic arthritis:forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.Arthritis Rheum,2007,56(2):476-488.
  • [16]Genovese MC,Mease PJ,Thomson GT,et al.Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.J Rheumatol,2007,34(5):1040-1050.
  • [17]Schiff MH,Burmester GR,Kent JD,et al.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.Ann Rheum Dis,2006,65(7):889-894.
  • [18]Scheinfeld N.Adalimumab:a review of side effects.Expert Opin Drug Saf,2005,4(4):637-641.
  • [19]Burmester GR,Mease P,Dijkmans BA,et al.Adalimumab safety and mortality rates from global clinical trials of six immunemediated inflammatory diseases.Ann Rheum Dis,2009,68(12):1863-1869.
  • [20]Patel RV,Clark LN,Lebwohl M,et al.Treatments for psoriasis and the risk of malignancy.J Am Acad Dermatol,2009,60(6):1001-1017.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615